These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8810344)

  • 1. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
    Pipe SW; Kaufman RJ
    J Biol Chem; 1996 Oct; 271(41):25671-6. PubMed ID: 8810344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
    Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
    Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
    Kroner PA; Foster PA; Fahs SA; Montgomery RR
    Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.
    Amano K; Sarkar R; Pemberton S; Kemball-Cook G; Kazazian HH; Kaufman RJ
    Blood; 1998 Jan; 91(2):538-48. PubMed ID: 9427707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
    J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes.
    Suzuki H; Shima M; Arai M; Kagawa K; Fukutake K; Kamisue S; Nakai H; Morichika S; Tanaka I; Inoue M; Gale K; Tuddenham EG; Yoshioka A
    Thromb Haemost; 1997 May; 77(5):862-7. PubMed ID: 9184393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
    Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
    Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.
    Ogata K; Selvaraj SR; Miao HZ; Pipe SW
    J Thromb Haemost; 2011 Jun; 9(6):1183-90. PubMed ID: 21645226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.
    d'Oiron R; Lavergne JM; Lavend'homme R; Benhida A; Bordet JC; Negrier C; Peerlinck K; Vermylen J; Saint-Remy JM; Jacquemin M
    Blood; 2004 Jan; 103(1):155-7. PubMed ID: 12969981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII.
    Tagliavacca L; Moon N; Dunham WR; Kaufman RJ
    J Biol Chem; 1997 Oct; 272(43):27428-34. PubMed ID: 9341195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
    Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization.
    Schneppenheim R; Lenk H; Obser T; Oldenburg J; Oyen F; Schneppenheim S; Schwaab R; Will K; Budde U
    Thromb Haemost; 2004 Jul; 92(1):36-41. PubMed ID: 15213842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular trafficking of factor VIII to von Willebrand factor storage granules.
    Rosenberg JB; Foster PA; Kaufman RJ; Vokac EA; Moussalli M; Kroner PA; Montgomery RR
    J Clin Invest; 1998 Feb; 101(3):613-24. PubMed ID: 9449695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
    Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
    J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.
    Voorberg J; de Laaf RT; Koster PM; van Mourik JA
    Biochem J; 1996 Sep; 318 ( Pt 3)(Pt 3):931-7. PubMed ID: 8836140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of five associations of F8 missense mutations containing FVIII B domain mutations.
    Jourdy Y; Nougier C; Roualdes O; Fretigny M; Durand B; Negrier C; Vinciguerra C
    Haemophilia; 2016 Jul; 22(4):583-9. PubMed ID: 26915717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
    Saenko EL; Shima M; Gilbert GE; Scandella D
    J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.